The purpose of this study is evaluation of the safety and the efficacy of transanal local excision in patients with cT3 rectal cancer which was downstaged into ycT0-1 after neoadjuvant chemoradiotherapy.
This study is a prospective multicenter single-arm phase II clinical trial. Rectal cancer patients with cT3 stage will receive neoadjuvant chemoradiotherapy, and be evaluated the response of the tumor in 6 to 10 weeks after completion of neoadjuvant chemoradiotherapy. For those who have good response (ycT0-1) will underwent transanal local excision under the patients' agree.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
86
Local excision for rectal cancer with good response
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
RECRUITING3-year disease free survival
Death or recurrence as an event
Time frame: 1-5 years
Complete response rate
The rate of complete response of the tumor after neoadjuvant chemoradiotherapy
Time frame: 1-5 years
Overall survival rate
Death as an event
Time frame: 1-5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.